TSE:GUD Knight Therapeutics (GUD) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free GUD Stock Alerts C$5.91 +0.09 (+1.55%) (As of 05/3/2024 ET) Add Compare Share Share Today's RangeC$5.82▼C$5.9450-Day RangeC$5.23▼C$5.9152-Week RangeC$4.35▼C$5.95Volume55,497 shsAverage Volume70,575 shsMarket CapitalizationC$597.91 millionP/E RatioN/ADividend YieldN/APrice TargetC$6.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Get Knight Therapeutics alerts: Email Address Knight Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside12.2% UpsideC$6.63 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 4 Articles This WeekInsider TradingAcquiring SharesC$1.88 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.07 out of 5 stars 2.3 Analyst's Opinion Consensus RatingKnight Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageKnight Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GUD. Previous Next 0.0 Dividend Strength Dividend YieldKnight Therapeutics does not currently pay a dividend.Dividend GrowthKnight Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GUD. Previous Next 1.9 News and Social Media Coverage News SentimentKnight Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Knight Therapeutics this week, compared to 0 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Knight Therapeutics insiders have bought 2,791.53% more of their company's stock than they have sold. Specifically, they have bought C$1,875,300.00 in company stock and sold C$64,855.00 in company stock.Percentage Held by Insiders46.45% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.67% of the stock of Knight Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Knight Therapeutics is -36.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Knight Therapeutics is -36.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.Price to Book Value per Share RatioKnight Therapeutics has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsFW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here. About Knight Therapeutics Stock (TSE:GUD)Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.Read More GUD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GUD Stock News HeadlinesApril 16, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 10,900 SharesApril 9, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Insider Buys C$32,550.00 in StockMay 5, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.May 3, 2024 | americanbankingnews.comKnight Therapeutics (TSE:GUD) PT Raised to C$5.40 at Stifel NicolausApril 21, 2024 | investing.comKnight Therapeutics Inc (GUD)April 16, 2024 | msn.comTSX Healthcare in April 2024: The Best Stocks to Buy Right NowApril 9, 2024 | finance.yahoo.comKnight to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceMarch 23, 2024 | investing.comEarnings call: Knight Therapeutics announced record revenues of $343 millionMay 5, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 22, 2024 | finance.yahoo.comKnight Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 20, 2024 | ca.finance.yahoo.comKnight Therapeutics Inc (04K.SG)March 14, 2024 | ca.finance.yahoo.comStocks in play: Knight Therapeutics Inc.March 7, 2024 | finance.yahoo.comFavourable Signals For Knight Therapeutics: Numerous Insiders Acquired StockFebruary 29, 2024 | ca.finance.yahoo.comStocks in play: Knight Therapeutics Inc.,February 29, 2024 | msn.comKnight Therapeutics launches Minjuvi in BrazilFebruary 21, 2024 | finance.yahoo.comKnight Therapeutics Announces Regulatory Submission of Fostamatinib in BrazilJanuary 4, 2024 | finance.yahoo.comKnight Therapeutics Announces Product Launch for IMVEXXY® in CanadaDecember 19, 2023 | finance.yahoo.comKnight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in CanadaOctober 2, 2023 | finance.yahoo.comKnight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing CompaniesSeptember 14, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc flat on Thursday (GUD)August 12, 2023 | markets.businessinsider.comKnight Therapeutics (KHTRF) Receives a Buy from RBC CapitalAugust 10, 2023 | theglobeandmail.comTrading For This Specialty Pharma Company is up Following Second Quarter ResultsAugust 10, 2023 | finance.yahoo.comKnight Therapeutics Reports Second Quarter 2023 ResultsAugust 3, 2023 | finance.yahoo.comNotice of Knight Therapeutics' Second Quarter 2023 Results Conference CallJune 7, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc up on Tuesday (GUD)June 2, 2023 | finance.yahoo.comKnight to Present at the Jefferies 2023 Healthcare Conference in New York CityMay 31, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc down on Wednesday (GUD)See More Headlines Receive GUD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/04/2024Next Earnings (Confirmed)5/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:GUD CUSIPN/A CIKN/A Webwww.gud-knight.com Phone514-484-4483FaxN/AEmployees725Year FoundedN/APrice Target and Rating Average Stock Price TargetC$6.63 High Stock Price TargetC$7.50 Low Stock Price TargetC$5.40 Potential Upside/Downside+12.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.16) Trailing P/E RatioN/A Forward P/E Ratio292.35 P/E Growth-1013.5Net IncomeC$-16,840,000.00 Net Margins-5.13% Pretax MarginN/A Return on Equity-2.14% Return on Assets0.40% Debt Debt-to-Equity Ratio9.25 Current Ratio3.20 Quick Ratio1.79 Sales & Book Value Annual SalesC$328.20 million Price / Sales1.82 Cash FlowC$1.54 per share Price / Cash Flow3.85 Book ValueC$7.38 per share Price / Book0.80Miscellaneous Outstanding Shares101,170,000Free FloatN/AMarket CapC$597.91 million OptionableNot Optionable Beta0.49 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Jonathan Ross Goodman B.A. (Age 55)L.L.B., M.B.A., Executive Chairman Comp: $250.94kMs. Samira Sakhia BCom (Age 56)CA, CPA, MBA, President, CEO & Director Comp: $674.28kMr. Arvind UtchanahChief Financial OfficerMs. Amal Khouri B.Sc.M.B.A., Chief Business OfficerMr. Jeff MartensGlobal Vice President of CommercialMr. Stephani SaverioVice President of Business DevelopmentMr. Leopoldo BosanoVice-President of Manufacturing & OperationsMs. Monica PercarioGlobal Vice President of Scientific AffairsMr. Henrique DiasGlobal Director of MarketingMs. Susan Caroline EmblemGlobal Vice President of Human ResourcesMore ExecutivesKey CompetitorsAurora CannabisTSE:ACBOrganigramTSE:OGISupreme CannabisTSE:FIREESSA PharmaCVE:EPIICC LabsCVE:ICCView All CompetitorsInsidersSime ArmoyanSold 10,900 sharesTotal: C$64,855.00 ($5.95/share)Sime ArmoyanBought 6,200 shares on 4/1/2024Total: C$32,550.00 ($5.25/share)Sime ArmoyanBought 351,000 shares on 3/25/2024Total: C$1.84 M ($5.25/share)Sime ArmoyanSold 28,200 sharesTotal: C$162,150.00 ($5.75/share)Sime ArmoyanSold 91,000 sharesTotal: C$523,250.00 ($5.75/share)View All Insider Transactions GUD Stock Analysis - Frequently Asked Questions Should I buy or sell Knight Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GUD shares. View GUD analyst ratings or view top-rated stocks. What is Knight Therapeutics' stock price target for 2024? 3 equities research analysts have issued 12 month price targets for Knight Therapeutics' shares. Their GUD share price targets range from C$5.40 to C$7.50. On average, they anticipate the company's stock price to reach C$6.63 in the next year. This suggests a possible upside of 12.2% from the stock's current price. View analysts price targets for GUD or view top-rated stocks among Wall Street analysts. How have GUD shares performed in 2024? Knight Therapeutics' stock was trading at C$5.19 at the beginning of 2024. Since then, GUD shares have increased by 13.9% and is now trading at C$5.91. View the best growth stocks for 2024 here. When is Knight Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GUD earnings forecast. How were Knight Therapeutics' earnings last quarter? Knight Therapeutics Inc. (TSE:GUD) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.05. The business had revenue of $74.20 million for the quarter, compared to analyst estimates of $78.37 million. Knight Therapeutics had a negative net margin of 5.13% and a negative trailing twelve-month return on equity of 2.14%. What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Bombardier, Inc. Class B (BBD.B), Brookfield Infrastructure Partners (BIP.UN), Enbridge (ENB), Spin Master (TOY), Alimentation Couche-Tard (ATD.B), Chemtrade Logistics Income Fund (CHE.UN), Canadian National Railway (CNR), Dollarama (DOL) and Extendicare (EXE). How do I buy shares of Knight Therapeutics? Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:GUD) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.